
Join to view full profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Fax+1 773-834-0778
Dr. Stock is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1989 - 1993
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Rush Medical College of Rush University Medical CenterClass of 1985
Certifications & Licensure
IL State Medical License 1987 - 2029
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.Wendy Stock, Ryan D Cassaday, Daniel J DeAngelo, Anjali Advani, Nicola Gokbuget
Targeted Oncology. 2026-09-16 - Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.Fieke W Hoff, Joshua F Zeidner, Geeta Torlapati, Deedra Nicolet, Krzysztof Mrózek
American Journal of Hematology. 2026-09-01 - Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a ger...Samuel J Yates, Elizabeth Terman, Lauren Miller, John F Cursio, Claire Wild
Leukemia. 2026-08-31
Journal Articles
- Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic LeukaemiaMichael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
Abstracts/Posters
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsWendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic LymphomaWendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSWendy Stock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- New Data and Paradigms in ALL: Insights and Applications61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Adult Clinical Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Other
- Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALLWendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2013-04-03 - Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALLWendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2012-02-07 - Taking a "BiTE Out of ALL" - Blinatumomab Approval for MRD Positive ALLWendy Stock, MD, Blood
https://www.doximity.com/articles/2ea81880-9840-4293-9145-ee93fb45e452
UpToDate, Wolters Kluwer Health - 2012-09-10
Press Mentions
TBI-Free Conditioning Before Transplant Effective in MRD-Negative B-ALLDecember 7th, 2025
Potential Game-Changing Impact on Mismatched Unrelated Blood Cell TransplantationDecember 7th, 2025
Advances in Technology Help Improve Safety and Access to Blood Cancer TherapiesDecember 6th, 2025
Grant Support
- Program 2 (Molecular Genetics And Hematopoiesis)National Cancer Institute2008–2012
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: